References
- Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193-203. doi: 10.1038/nrc1816.
- Icabucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975-83. doi: 10.1200/JCO.2016.70.7836.
- Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747–56. doi: 10.1002/bdra.20294.
- Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–9. doi: 10.1016/S0140-6736(99)05264-2.
- Hasle H, Clemmensen IH, Mikkelsen M. Incidence of cancer in individuals with Down syndrome. Tidsskr Nor Laegeforen. 2000;120:2878–81.
- Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.
- Harigae H. GATA transcription factors and hematological diseases. Tohoku J Exp Med. 2006;210:1–9. doi: 10.1620/tjem.210.1.
- Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30:1816–23. doi: 10.1038/leu.2016.164.
- Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26(10):2204-11. doi: 10.1038/leu.2012.84.
- Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83. doi: 10.1182/blood-2007-09-114231.
- Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood. 2010;116(7):1045-50. doi: 10.1182/blood-2009-07-235291.
- Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-46. doi: 10.1038/ng.469.
- Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014;46(6):618–23. doi: 10.1038/ng.2949.
- Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, et al. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med. 2015;212(6):953–70. doi: 10.1084/jem.20150002.
- Tirado CA, Shabsovich D, Kim Y, et al. A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements. Biomark Res. 2015;3:11. doi: 10.1186/s40364-015-0036-1. eCollection 2015.
- Hertzberg L, Vendramini E, Ganmore I, Traum P, Pullarkat S, Kallen M, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006–17. doi: 10.1182/blood-2009-08-235408.
- Rampal R, Levine RL. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Bailliere's Best Practice in Clinical Haematology. 2014;27(2):83–93. doi: 10.1016/j.beha.2014.07.001.
- Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood. 2007;109(5):2202–4. doi: 10.1182/blood-2006-09-045963.
- Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484–92. doi: 10.1016/S0140-6736(08)61341-0.
- Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930–2. doi: 10.1111/j.1365-2141.2008.07552.x.
- Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646–8. doi: 10.1182/blood-2008-08-170928.
- Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med. 2010;14(3):504– 27. doi: 10.1111/j.1582-4934.2010.01018.x.
- Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f.
- Varsome, The Human Genomics Community; GATA3 c.778+1123T>C SNV | hg38 (varsome.com); GATA3(NM_001002295.2):c.779-1748C>A SNV | hg38 (varsome.com); PIP4K2A c.678+761C>G SNV | hg38 (varsome.com)
- Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688–98. doi: 10.1182/blood-2009-03-208397.
- Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010;107(1):252–7. doi: 10.1073/pnas.0911726107.
- Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20. doi: 10.1002/0471142905.hg0720s76.
- Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci U S A. 2017;114(20):E4030-E4039. doi: 10.1073/pnas.1702489114.
- Pieper K, Grimbacher B, Eibel H. B-Cell development and differentiation. J Allergy Clin Immunol. 2013;131(4):959-71. doi: 10.1016/j.jaci.2013.01.046.
- Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226-1231. doi: 10.1038/ng.2754.
- Auer F, Ruschendorf F, Gombert M, Husemann P. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia. 2014;28:1136-1138. doi: 10.1038/leu.2013.363.
- Winer P, Muskens IS, Walsh KM, Vora A, Moorman AV, Wiemels JL, et al. Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675. doi: 10.1182/bloodadvances.2019001216.
- Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021.
- Kuehn HS, Boisson B, Cunningham-Rundles C, Reichenbach J. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043. doi: 10.1056/NEJMoa1512234.
- Mullighan, CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–480. doi: 10.1056/NEJMoa0808253.
- Mullighan, CG, Goorha S, Radtke I, Miller BC, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. doi: 10.1038/nature05690.
- Sherborne AL, Hosking F, Prasad BR, Kumar R, Koehler R, Vijayakrishnan J, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010;42(6):492–494. doi: 10.1038/ng.585.
- Yoshino H, Nishiyama Y, Kamma H, Chiba T. Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. Int J Hematol. 2020;112(2):217-222. doi: 10.1007/s12185-020-02885-y.
- Poggi M, Canault M, Favier M, Turro E. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282-294. doi: 10.3324/haematol.2016.147694.
- Karastaneva A, Nebral K, Schlagenhauf A, Baschin M. Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor. J Med Genet. 2020;57(6):427-433. doi: 10.1136/jmedgenet-2019-106339.
- Liao W, Liu Y. Treatment outcomes in children with acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(29):e21015. doi: 10.1097/MD.0000000000021015.
- Bohnstedt C, Levinsen M, Rosthøj S, Zeller B, Taskinen M, Hafsteinsdottir S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acutelymphoblastic leukemia. Leukemia. 2013;27:866–70. doi: 10.1038/leu.2012.325.
- Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.
- Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE, et al. Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321–5. doi: 10.1136/adc.85.4.321.
- Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, et al. Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt- Münster Group. Leukemia. 1998;12:645–51. doi: 10.1038/sj.leu.2400989.
- Matloub Y, Rabin KR, Ji L, Devidas M, Hitzler J, Xu X, et al. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group. Blood Adv. 2019;3:1647–56. doi: 10.1182/bloodadvances.2019032094.
- Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2005;106:4043–9. doi: 10.1182/blood-2003-10-3446.
- Zipursky A. Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatric Research. 2000; 47(6): 704. doi: 10.1203/00006450-200006000-00002.
- Chiang JC, Jiang J, Newburger PE, Lawrence JB. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro. Nat Commun. 2018; 9(1): 5180. doi: 10.1038/s41467-018-07630-y.
- Laurent AP, Kotecha RS and Malinge S. Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. Leukemia. 2020;34:1984–1999. doi: 10.1038/s41375-020-0854-5.
- Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47:672–676. doi: 10.1038/ng.3301.
- Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;137–145. doi: 10.1182/asheducation-2018.1.137.
- Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–112. doi: 10.1038/nm.4439.
- Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun. 2014;5:4654. doi: 10.1038/ncomms5654.
- Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–1299. doi: 10.1038/ng.2759.
- de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49:451–456. doi: 10.1038/ng.3772.
- Kroll M, Kaupat-Bleckmann K, Mörickel A, Altenl J, Schewel DM, Stanullal M, Zimmermann M, Schrappe M, Cario G. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Haematologica. 2020;105(4):1013-1020. doi: 10.3324/haematol.2019.224774.